Previous 10 | Next 10 |
home / stock / wuxay / wuxay news
WuXi AppTec Reports Record First-Quarter In 2022 PR Newswire Revenue Up 71.2% Year-Over-Year to RMB8,474 Million Net Profit Attributable to Owners of the Company Up 9.5% Year-Over-Year to RMB1,643 Million Diluted Earnings Per Share (EPS)...
Wuhan Binhui Biopharm closed a $47 million Series B financing to support its R&D of oncolytic virus products. Amoy Diagnostics, a Shanghai novel molecular diagnostics company, signed a collaboration agreement to develop companion diagnostics for AstraZeneca drugs. Hangzhou Asc...
WuXi AppTec press release (OTCPK:WUXAY): FY Non-GAAP EPS of RMB1.75. Revenue of RMB22.9B (+38.5% Y/Y). For further details see: WuXi AppTec Non-GAAP EPS of RMB1.75, revenue of RMB22.9B
WuXi AppTec Reports Strong Revenue Growth in 2021 PR Newswire Revenue Up 38.5% Year-Over-Year to RMB22,902 Million Net Profit Attributable to Owners of the Company Up 72.2% Year-Over-Year to RMB5,097 Million Diluted Earnings Per Share (EPS) Up 6...
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies TESSA™ technology provides a scalable process for manufacturing gene therapies, accelerating the production of large quantities of therapeutic DNA req...
Statement by WuXi AppTec Regarding Recent Market Fluctuation PR Newswire SHANGHAI , Dec. 15, 2021 /PRNewswire/ -- Our company's activities continue apace and we remain confident in our platform, which enables our global customers and serves patients around the wo...
WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan PR Newswire SHANGHAI , Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a l...
WuXi AppTec (OTCPK:WUXAY): Q3 Non-GAAP EPS of RMB0.46; GAAP EPS of RMB0.30. Revenue of RMB5.98B (+30.6% Y/Y) Press Release For further details see: WuXi AppTec reports Q3 results
WuXi AppTec Reports Strong Third-Quarter 2021 Results PR Newswire Revenue Up 30.6% Year-Over-Year to RMB5,985 Million Net Profit Attributable to Owners of the Company Up 36.2% Year-Over-Year to RMB887 Million Diluted EPS Up 30.4% Year-Over-Year&...
WuXi AppTec Receives AA ESG Rating from MSCI WuXi AppTec upgraded to an AA environmental, social and governance (ESG) rating by Morgan Stanley Capital International PR Newswire SHANGHAI , Sept. 5, 2021 /PRNewswire/ -- WuXi AppTec ("the Company") is pleas...
News, Short Squeeze, Breakout and More Instantly...
Wuxi AppTec Co. Ltd. ADR Company Name:
WUXAY Stock Symbol:
OTCMKTS Market:
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations PR Newswire Revenue Reached RMB7,982 Million ; Excluding COVID-19 Commercial Projects, Down 1.8% Net Profit Attributable to the Owners of the Company Reached...
WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...